Financial results overview for the fiscal year ended March 31, 2023
In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.
●Consolidated net sales totaled 198,380 million yen, an increase of 13,574 million yen (7.3%) year-on-year. Sales in the pharmaceuticals business underperformed, while the functional chemicals and safety systems businesses outperformed the previous fiscal year.
●Consolidated operating income totaled 21,505 million yen, an increase of 454 million yen (2.2%) year-on-year, outperforming the previous fiscal year in the pharmaceuticals and safety systems businesses, while underperforming in the functional chemicals industry.
●Consolidated ordinary income totaled 23,025 million yen, a decrease of 128 million yen (0.6%) year-on-year.
●Profit attributable to owners of parent was 14,984 million yen, a decrease of 2,196 million yen (12.8%) year-on-year, owing to recognition of an impairment loss on property, plant, and equipment.
Segments Data（Net sales・Operating income by business segment）
※Segment profit is reported as operating income after the allocation of corporate expenses until the fiscal year ended March 2020, and from the fiscal year ended March 2021, operating income before the allocation of corporate expenses is reported as segment profit.
provided by StockWeather.com,Inc.
